Drugs News and Research

RSS

Novartis’ investigational compound achieves overall response rate of 58% in patients with ALK+ NSCLC

Novartis today announced that The New England Journal of Medicine (NEJM) published clinical trial results showing the investigational compound LDK378 (ceritinib) achieved an overall response rate (ORR, including complete response [CR] and partial response [PR]) of 58% and a median progression-free survival (PFS) of seven months in adults with advanced anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC) who received 400 mg or higher of LDK378 per day.

28 Mar 2014

Viewpoints: Generic drug warnings; Medicare Advantage 'scam'

Late last year, the Food and Drug Administration proposed sensible regulations that would authorize the makers of generic drugs to update safety labels independently, without waiting for F.D.A. approval, to warn of newly discovered risks.

28 Mar 2014

Antidepressant medications during pregnancy linked with increased rates of preterm birth

Antidepressant medications taken by pregnant women are associated with increased rates of preterm birth. This finding reinforces the notion that antidepressants should not be used by pregnant women in the absence of a clear need that cannot be met through alternative approaches, say researchers from Brigham and Women's Hospital, Vanderbilt University, MetroWest Medical Center, and Tufts Medical Center.

28 Mar 2014

Retrophin acquires Manchester Pharmaceuticals

Retrophin, Inc. today announced the completion of the previously announced acquisition of Manchester Pharmaceuticals LLC for a total of $62.5 million, including an upfront payment of $29.5 million, plus other payments based on product sales.

27 Mar 2014

RuiYi declares $15M Series B financing to advance monoclonal antibodies targeting GPCR receptors

RuiYi, Inc. announced today a $15 million Series B financing by existing investors: 5AM Ventures, Versant Ventures, Apposite Capital, SR One, the independent corporate healthcare venture capital fund of GlaxoSmithKline, Merck Serono Ventures, the strategic corporate venture fund of Merck Serono, and Aravis SA.

27 Mar 2014

New drug multiplies analgesic effect of opioids without increasing constipation

Scientists from the University of Granada have taken part, alongside the Esteve laboratory, in the development of a new drug that multiplies the analgesic effect of opioids (drugs for treating intense pain), without increasing constipation, one of the most common side-effects of these drugs, among which is morphine.

27 Mar 2014

Study to understand how protein motor works for development of targeted cancer therapies

Researchers at Warwick Medical School have shown for the first time how a protein motor, Kif15, uses acrobatic flexibility to navigate within the mitotic spindle. Understanding how it works could prove vital for the development of targeted cancer therapies.

27 Mar 2014

Senhwa Biosciences to present CX-5461 study results at AACR meeting

Senhwa Biosciences, Inc. announced today that results from research with its first-in-class Pol I inhibitor, CX-5461, will be presented at the 2014 American Association for Cancer Research (AACR) annual meeting held on April 5-9 in San Diego, CA.

27 Mar 2014

Baxter plans to create two independent global healthcare companies

Baxter International Inc. today announced plans to create two separate, independent global healthcare companies -- one focused on developing and marketing innovative biopharmaceuticals and the other on life-saving medical products. Both will be global leaders in their respective markets.

From Baxter International Inc. 27 Mar 2014

pSivida resubmits New Drug Application for ILUVIEN

pSivida Corp., a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the New Drug Application for ILUVIEN for the treatment of chronic Diabetic Macular Edema has been resubmitted to the U.S. Food and Drug Administration (FDA).

27 Mar 2014

Researchers develop fluorescent sensor to identify presence of drug in less than 30 seconds

A team of researchers from the National University of Singapore (NUS) has developed the world's first fluorescent sensor to identify the presence of a drug known as GHB that is commonly used to spike beverages.

27 Mar 2014

Experimental vaccine for HSV-2 infection reduces rate of viral shedding at 6 months

Updated Phase 1/2a results with GEN-003, a vaccine candidate under development by Genocea Biosciences, Inc. (Nasdaq: GNCA) for the treatment of herpes simplex virus type 2 (HSV-2) infection, showed the experimental vaccine to generate highly significant reductions in both the number of clinical lesion days and rate of viral shedding at six months after the final vaccine dose.

27 Mar 2014

Research points strong reason to develop new class of antidepressant drug

Scientists have shown for the first time that a chemical in the brain called galanin is involved in the risk of developing depression.

From The University of Manchester 27 Mar 2014

Cost controls key for insurers participating in Federal Employee Health Plan

The Office of Personnel Management has urged companies participating in the Federal Employees Health Benefits Program to boost their efforts to hold down the cost of prescription drugs.

27 Mar 2014

New era of lung cancer therapy close to dawning

A new era of lung cancer therapy is close to dawning, using drugs that can prevent tumour cells from evading the immune system, experts have said at the 4th European Lung Cancer Congress.

27 Mar 2014

Adult offspring of addicted parents more likely to have arthritis

The adult offspring of parents who were addicted to drugs or alcohol are more likely to have arthritis, according to a new study by University of Toronto researchers.

27 Mar 2014

Johns Hopkins researchers identify protein that regulates the body's immune response to CMV

Infectious disease specialists at the Johns Hopkins Children's Center have identified a protein that regulates the body's immune response to cytomegalovirus (CMV), a common pathogen that causes lifelong infections and can lead to devastating illness in newborns and those with weakened immune systems.

27 Mar 2014

Drugs News and Research

Novartis’ investigational compound achieves overall response rate of 58% in patients with ALK+ NSCLC

Viewpoints: Generic drug warnings; Medicare Advantage 'scam'

Antidepressant medications during pregnancy linked with increased rates of preterm birth

Retrophin acquires Manchester Pharmaceuticals

RuiYi declares $15M Series B financing to advance monoclonal antibodies targeting GPCR receptors

New drug multiplies analgesic effect of opioids without increasing constipation

Study to understand how protein motor works for development of targeted cancer therapies

Senhwa Biosciences to present CX-5461 study results at AACR meeting

Baxter plans to create two independent global healthcare companies

pSivida resubmits New Drug Application for ILUVIEN

Researchers develop fluorescent sensor to identify presence of drug in less than 30 seconds

Experimental vaccine for HSV-2 infection reduces rate of viral shedding at 6 months

Research points strong reason to develop new class of antidepressant drug

Cost controls key for insurers participating in Federal Employee Health Plan

New era of lung cancer therapy close to dawning

Adult offspring of addicted parents more likely to have arthritis

Johns Hopkins researchers identify protein that regulates the body's immune response to CMV

Expert highlights the importance of gender-specific approach for treating diabetes mellitus

Mephedrone drug causes acute withdrawal symptoms, shows study

Researchers evaluate influence of gut microbes on function of immune cells

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News